In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
Multidisciplinary care influenced therapy choices but did not substantially shorten treatment delays for patients with ...
Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.
A retrospective chart review finds that Black patients with atopic dermatitis report fewer dupilumab-associated adverse ...
SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback